share_log

阳光诺和(688621.SH):目前已有12款创新药纳入研发储备

Sunshine Novo (688621.SH): Currently, 12 Innovative Drugs have been included in the research and development reserve.

Gelonghui Finance ·  Dec 19 16:50

On December 19, Glonghui reported that Sunshine Novo (688621.SH) stated on the investor interaction platform that the company's main Business focuses on drug research services. Due to the different stages of research projects, there are variations in execution cycles. During the project advancement process, the company adheres to the principle of phased payments and recognizes revenue based on R&D progress or the delivery of final results; therefore, the company's business itself does not exhibit quarterly cyclical characteristics. Short-term market fluctuations do not accurately reflect the intrinsic value of the enterprise. In recent years, the company has gradually increased its investment in R&D, particularly in the field of Innovative Drugs, through independent research and collaborative efforts, continually deepening its pipeline layout in core areas such as pain relief, kidney disease and Hemodialysis, oncology support, cardiovascular and cerebrovascular diseases, and antibacterial medications. Currently, 12 Innovative Drugs are included in R&D reserves, among which the research and development of 'STC007 injection' is progressing rapidly and has entered Phase II clinical trials.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment